Tier 1 — highest

Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature

Alfonso E. Bello, Steffen Oesser
Current Medical Research and Opinion 2006 22(11):2221–2232

Bibliography

DOI
10.1185/030079906X148373
PubMed
PMID 17076983
Funding
This review was funded by GELITA Health Products, Vernon Hills, Illinois.
Competing interests
No explicit competing interests declaration beyond funding statement. Review funded by GELITA Health Products — a commercial collagen hydrolysate manufacturer. Co-author Steffen Oesser was affiliated with Collagen Research Institute (Kiel, Germany), a research entity closely tied to GELITA AG. Lead author Alfonso E. Bello, MD, was Clinical Associate Professor at University of Illinois College of Medicine at Chicago at time of publication. Substantial commercial conflict of interest — the review was funded and co-authored by parties with direct commercial interest in the reviewed product.

Study snapshot

DesignNarrative review of preclinical and clinical literature on collagen hydrolysate for osteoarthritis and joint disorders
ModelLiterature review — covers in vitro chondrocyte studies, animal models, and 7 identified clinical trials (4 open-label, 3 double-blind)
SampleNot applicable — review paper. Aggregate clinical evidence across ~700 patients in reviewed trials.
InterventionNot applicable — review methodology. Trials covered used oral collagen hydrolysate at doses ranging 7–10 g/day, durations 8 weeks to 6 months, in OA of knee, hip, or other joints.
DurationPubMed searches through May 2006 without date limits; German medical literature reviewed based on author judgement of relevance
EndpointsSynthesis of collagen hydrolysate absorption evidence; Chondrocyte extracellular matrix synthesis stimulation (p < 0.05); Clinical pain reduction (VAS, WOMAC); Joint function outcomes; Safety across trials

What the study showed, in plain terms

By 2006, several small clinical trials had suggested that swallowing collagen daily might reduce pain in people with osteoarthritis of the knee or hip. At the same time, laboratory experiments had shown that collagen peptides accumulate in cartilage after ingestion and stimulate cartilage cells to make more of their own extracellular matrix. What the field lacked was a single comprehensive synthesis of what all this evidence added up to — a document that clinicians, researchers, and interested consumers could use as a starting point.

Alfonso Bello (a rheumatologist at the University of Illinois) and Steffen Oesser (a researcher at the Collagen Research Institute in Germany) wrote exactly that review. They searched PubMed comprehensively through May 2006 for all published research on collagen hydrolysate in osteoarthritis and joint disorders, and also included several German-language studies not indexed in PubMed. They summarised what was known about how collagen peptides are absorbed, how they might work at the cellular level in cartilage, and what the seven identified clinical trials had shown.

The review concluded that a growing body of evidence supported collagen hydrolysate as a defensible option for osteoarthritis symptom management. Ingested collagen peptides accumulate specifically in cartilage. In laboratory studies, they stimulate cartilage cells (chondrocytes) to significantly increase synthesis of extracellular matrix macromolecules (p < 0.05). Across the seven clinical trials — some of which had methodological weaknesses — collagen hydrolysate was consistently found to be safe and to produce improvement in pain and function outcomes for at least some patients. This review remains the standard first citation for anyone writing about oral collagen for joint health, and every subsequent joint-focused trial (Clark 2008, Benito-Ruiz 2009, Zdzieblik 2017, and others) cites it as the umbrella literature reference.

Key findings

  • Orally administered collagen hydrolysate is absorbed intestinally and accumulates specifically in cartilage tissue, demonstrated in radiolabelled tracer studies.
  • Collagen hydrolysate ingestion stimulates a statistically significant increase (p < 0.05) in synthesis of extracellular matrix macromolecules by chondrocytes in laboratory cell culture experiments — a mechanistic rationale for clinical effect.
  • Four open-label and three double-blind clinical trials identified — all showed collagen hydrolysate to be safe and to provide improvement in some measures of pain and function in some patients with osteoarthritis or other arthritic conditions.
  • Multiple German-language studies (not PubMed-indexed) contribute additional evidence, though methodological transparency varies.
  • Effective dose range across reviewed trials: approximately 7–10 g/day, typical duration 12 weeks to 6 months for symptomatic effect.
  • Safety profile favourable across all reviewed trials — no serious adverse events attributed to collagen hydrolysate.
  • Concludes: "A growing body of evidence provides a rationale for the use of collagen hydrolysate for patients with OA."

What this study can and cannot tell us

  • Narrative review, not a systematic review — no formal quality-scoring of included studies, no meta-analysis, no assessment of risk of bias using standardised tools (PRISMA/GRADE were not commonly applied at time of publication).
  • Substantial commercial conflict of interest — funded by GELITA Health Products (a commercial collagen hydrolysate manufacturer), and co-author Steffen Oesser is affiliated with Collagen Research Institute (Gelita-linked).
  • Includes German-language studies "based on the authors' judgment of their relevance" — introduces selection bias.
  • Many reviewed trials had methodological weaknesses openly acknowledged by the authors — small sample sizes, lack of blinding, missing statistical significance details.
  • Published 2006 — pre-dates the well-conducted Clark 2008, Benito-Ruiz 2009, Zdzieblik 2017, and later trials that provide stronger evidence. Serves as a historical foundation, not a current state-of-evidence document.
  • Focuses on osteoarthritis; other joint conditions (rheumatoid arthritis, sports-related joint discomfort) covered more superficially.
  • Efficacy conclusions are qualified — "improvement in some measures of pain and function in some men and women" is a modest claim that reflects the heterogeneity of the underlying evidence.

Related papers in the corpus

Tier 4
Bone broth unlikely to provide reliable concentrations of collagen precursors compared to supplemental sources of collagen used in collagen research
Rebekah D. Alcock et al. · International Journal of Sport Nutrition and Exercise Metabolism · 2019
Tier 4
Assessment of effectiveness of oral administration of collagen peptide on bone metabolism in growing and mature rats
Jian Wu et al. · Journal of Bone and Mineral Metabolism · 2004
Tier 4
Assessment of bioavailability after in vitro digestion and first pass metabolism of bioactive peptides from collagen hydrolysates
Christina E. Larder et al. · Current Issues in Molecular Biology · 2021
Reviewed by , Medical Advisory Board · Last verified against PubMed on 30 August 2026